Palisade Bio, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
PALI Nasdaq 2830 www.palisadebio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Palisade Bio, Inc.

Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development - Aug 10th, 2026 2:20 pm
Palisade Bio Draws Bullish Call, Lead IBD Drug Advances Toward Phase 2 - Jul 27th, 2026 5:30 am
Palisade Bio to Participate in the Leerink Partners Therapeutics Forum - Jul 10th, 2026 7:00 am
PALISADES GOLDCORP APPOINTS DECORATED COMBAT VETERAN AND FORMER SENIOR ADVISOR TO THE U.S. SECRETARY OF DEFENSE, COLONEL DOUGLAS MACGREGOR (RET.), TO ITS BOARD OF DIRECTORS - Jul 6th, 2026 4:30 am
PALI Stock Heads For Best Day In Seven Months – What’s Driving Today’s Rally? - Jun 29th, 2026 11:49 am
Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis - Jun 29th, 2026 6:30 am
Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors - Jun 11th, 2026 6:45 am
Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn’s Disease at New York Academy of Sciences Symposium - Jun 9th, 2026 6:45 am
Palisade Bio to Participate in the Jefferies Global Healthcare Conference - May 27th, 2026 7:00 am
Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline - May 21st, 2026 3:51 pm
Why This Fund Added $12 Million to a Biotech Stock That's Now Down 58% in a Year - May 21st, 2026 3:39 pm
Palisade Bio (PALI) Reports Q1 2026 Results as R&D Expenses Rise to $6.4M - May 17th, 2026 10:49 pm
We're Not Worried About Palisade Bio's (NASDAQ:PALI) Cash Burn - May 15th, 2026 5:00 am
Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108 - May 12th, 2026 2:15 pm
Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative Colitis - May 5th, 2026 6:30 am
Wolfe Highlights Differentiation Potential in Palisade Bio, Inc. (PALI) Clinical Profile - Apr 17th, 2026 7:57 am
Palisade Bio to Present at the Needham & Co. 25th Annual Healthcare Conference - Apr 8th, 2026 7:00 am